The European Respiratory Society (ERS), organized its 29th congress from 28 September to 02 October 2019 in Madrid, Spain. Showcasing the excellence of respiratory medicine, it is an essential event for all pneumology professionals and the patient associations concerned. It brings together more than 15,000 doctors, scientists and other specialists in respiratory medicine (research laboratories, etc.).
This event promotes scientific research and provides access to educational resources on diseases such as asthma, the heart of the Optimhal-Protecsom laboratory.
Promising resultats presented by OptimHal-ProtecSom
The Optimhal-Protecsom laboratory actively participated in this knowledge sharing by presenting its latest research on several inhalation chambers for mechanical ventilation circuits, including Combihaler.
Combihaler® is an inhalation chamber for mechanical ventilation systems. It allows for the simultaneous administration of metered-dose drugs and a mesh nebulizer.
In this study, the in vitro performances of several spacers, including CombiHaler®, were evaluated for drug delivery with pressurized metered dose inhaler (pMDI) and vibrating mesh nebulizer, in comparison with T adapters usually used, in an adult mechanical ventilation model.
Results showed that in vitro drug delivery is higher when using a spacer instead of T pieces, with both a pMDI and a vibrating mesh nebulizer.
CombiHaler has similar or higher in vitro performances than other spacers and permits the use of both a pMDI and a vibrating mesh nebulizer without dismantling the breathing circuit : these are new successful results which strengthen our goals and our purpose of continuous improvement.
Each year, the Optimhal-Protecsom laboratory invests more than 25% of its turnover in research. This is an essential point for designing tomorrow’s medical devices with a constant goal : to improve the quality of life of patients and facilitate the work of caregivers.